natgillin/translations-raw huggingface dataset:
Additional side effects have been reported after this medicine was marketed.
Dodatne nuspojave prijavljene su nakon stavljanja lijeka na tržište.
Additional side effects have been seen in patients using eye drops containing bimatoprost and so may possibly be seen with GANFORT single-dose:
Dodatne nuspojave zabilježene su kod bolesnika koji primjenjuju kapi za oko koje sadrže bimatoprost, stoga se mogu pojaviti i s jednodoznim GANFORT-om:
Additional side effects have been seen in patients using eye drops containing bimatoprost and so may possibly be seen with GANFORT:
Dodatne nuspojave zabilježene su kod bolesnika koji primjenjuju kapi za oko koje sadrže bimatoprost, stoga se mogu pojaviti i s GANFORT-om:
Additional side effects have been seen in patients using eye drops containing timolol and so may possibly be seen with GANFORT single-dose.
Dodatne nuspojave zabilježene su kod bolesnika koji primjenjuju kapi za oko koje sadrže timolol, stoga se mogu pojaviti i s jednodoznim GANFORT-om.
Additional side effects have been seen in patients using eye drops containing timolol and so may possibly be seen with GANFORT.
Dodatne nuspojave zabilježene su kod bolesnika koji primjenjuju kapi za oko koje sadrže timolol, stoga se mogu pojaviti i s GANFORT-om.
Additional side effects in adults receiving chemotherapy for cancer
Dodatne nuspojave u odraslih koji primaju kemoterapiju zbog raka
Additional side effects in children and adolescents
Dodatne nuspojave kod djece i adolescenata
Additional side effects in children and adolescents hyperactivity
Dodatne nuspojave u djece i adolescenata hiperaktivnost.
Additional side effects in people donating their own blood before surgery
Dodatne nuspojave u bolesnika koji daju vlastitu krv prije operacije
Additional side effects in people with chronic kidney disease (renal anaemia)
Dodatne nuspojave u osoba s kroničnom bolesti bubrega (bubrežna anemija)
Additional side effects observed when Ceplene was used in other types of treatment: Very common side effects (may affect more than 1 in 10 people)
Dodatne nuspojave uočene kada se Ceplene primjenjivao s drugim vrstama liječenja: Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba)
Additional side effects that occurred during routine use of very similar combined or individual hepatitis A and hepatitis B vaccines were as follows:
Dodatne nuspojave koje su se javile tijekom rutinske primjene vrlo sličnih kombiniranih ili pojedinačnih cjepiva za hepatitis A i hepatitis B bile su sljedeće:
Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Dodatni znakovi mogu uključivati povišenu kreatin fosfokinazu, mioglobinuriju (rabdomiolizu) i akutno zatajenje bubrega.
Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Od dodatnih znakova mogu se javiti povišena vrijednost kreatin fosfokinaze, mioglobinurija (rabdomioliza) i akutno zatajenje bubrega.
Additional studies (known as pharmacokinetic studies) compared the levels of insulin glargine in the blood obtained after administering the two strengths.
Dodatnim ispitivanjima (poznatim kao farmakokinetička ispitivanja) uspoređena je razina inzulina glargina u krvi dobivena primjenom dvije jačine lijeka.
Additional studies involving patients with genotypes 4 indicate that Daklinza is also as effective against genotype 4 as it is against genotype 1.
Dodatna ispitivanja koja su obuhvatila bolesnike s genotipom 4 indiciraju da je Daklinza također djelotvoran protiv genotipa 4 kao i protiv genotipa 1.
Additional studies looked at the combination of Pegasys and the hepatitis C medicine ribavirin in adults with chronic hepatitis C and included: one study comparing two doses and two durations of treatment (24 or 48 weeks) in 1,285 patients; one study comparing 16 and 24 weeks of treatment in 1,469 patients; one study in 514 patients with normal liver enzyme levels; one study in 860 patients who were also infected with HIV; and a final study in 950 patients who did not respond to previous treatment with peginterferon alfa-2b and ribavirin.
Dodatna ispitivanja proučavala su kombinaciju lijeka Pegasys i ribavirina protiv hepatitisa C kod odraslih s kroničnim hepatitisom C te su uključivala: jedno ispitivanje koje je uspoređivalo dvije doze i dva trajanja terapije (24 ili 48 tjedana) u 1285 bolesnika; jedno ispitivanje uspoređivalo je 16 i 24 tjedna liječenja u 1469 bolesnika; jedno ispitivanje na 514 bolesnika s normalnim razinama jetrenih enzima; jedno ispitivanje na 860 bolesnika koji su također bili zaraženi HIV-om; te konačno ispitivanje na 950 bolesnika koji nisu reagirali na prethodno liječenje pegineterferonom alfa-2b i ribavirinom.
Additional studies looked at the effects of booster vaccinations and vaccinations in older infants and children.
Dodatna su ispitivanja istražila djelovanje booster cjepiva i cjepiva u starije dojenčadi i djece.
Additional studies of the combination with peginterferon alfa and ribavirin involving patients with hepatitis C virus of genotype 4 and patients with HIV co-infection showed results consistent with those in patients with genotype 1.
Dodatna ispitivanja kombinacije s peginterferonom alfa i ribavirinom obuhvatila su bolesnike oboljele od virusa hepatitisa C genotipa 4 i bolesnike koji ujedno imaju infekciju HIV-om, a pokazala su rezultate konzistentne s onima u bolesnika s genotipom 1.
Additional studies showed that Sovaldi in combination with ribavirin decreased the risk of infection of the new liver with hepatitis C virus in patients undergoing transplantation, that Sovaldi is also effective in patients infected with both hepatitis C and HIV, and that the outcome of patients with genotype 3 infection could be improved by extending treatment to 24 weeks.
Dodatna su ispitivanja pokazala da lijek Sovaldi u kombinaciji s ribavirinom smanjuje rizik od infekcije presađene jetre virusom hepatitisa C u bolesnika koji su bili podvrgnuti transplantaciji, da je lijek Sovaldi također djelotvoran u bolesnika koji su zaraženi i virusom hepatitisa C i HIV-om te da se ishod u bolesnika s infekcijom genotipom 3 može poboljšati ako se liječenje produži na 24 tjedna.
Additional supplementation with vitamin D should be considered on an individual basis taking into account any vitamin D intake from vitamins and dietary supplements.
U bolesnica koje uzimaju FOSAVANCE mora se na individualnoj bazi razmotriti uzimanje dodatne količine vitamina D, a pri tome treba uzeti u obzir količinu vitamina D koju bolesnica unosi pripravcima vitamina ili dodacima prehrani.
Additional supplementation with vitamin D should be considered on an individual basis taking into account any vitamin D intake from vitamins and dietary supplements.
U bolesnica koje uzimaju VANTAVO mora se na individualnoj bazi razmotriti uzimanje dodatne količine vitamina D, a pri tome treba uzeti u obzir količinu vitamina D koju bolesnica unosi hranom i drugim nadomjescima vitamina.
Additional supplies which are not included in the pack (See Figure B):
Dodatan pribor koji nije uključen u pakiranje (vidjeti sliku B):
Additional symptoms included mild or moderate dyspnoea, hypoxia (oxygen saturation decreased), throat tightness, chest discomfort, flushing, pruritus, urticaria, face oedema, angioneurotic oedema, rhinitis, bronchospasm, tachypnoea, wheezing, hypertension, hypotension, tachycardia, palpitations, abdominal pain, nausea, vomiting, infusion-related pain including pain at the extremities, myalgia, and headache.
Ostali simptomi uključivali su blagu do umjerenu dispneju, hipoksiju (smanjenu saturaciju kisikom), stezanje u grlu, nelagodu u prsištu, crvenilo praćeno osjećajem užarenosti, pruritus, urtikariju, edem lica, angioneurotski edem, rinitis, bronhospazam, tahipneju, piskanje pri disanju, hipertenziju, hipotenziju, tahikardiju, palpitacije, bol u abdomenu, mučninu, povraćanje, bol povezanu s infuzijom uključujući bol u udovima, mijalgiju i glavobolju.
Additional syringes are provided in case more than one syringe is needed per day.
Dodatne štrcaljke se prilažu ako je potrebno više od jedne štrcaljke dnevno.
Additional syringes are provided in case more than one syringe is needed per day.
Dodatne štrcaljke su priložene za slučaj ako je potrebno više od jedne štrcaljke dnevno.
Additional syringes are provided in the starter pack in case more than one syringe is needed per day.
U početnom pakiranju priložene su i dodatne štrcaljke u slučaju da je potrebno više od jedne štrcaljke dnevno.
Additional syringes can be obtained from the pharmacy.
Dodatne štrcaljke mogu se nabaviti u ljekarni.
Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Tijekom razdoblja stresa ili elektivnog kirurškog zahvata potrebno je razmotriti dodatnu terapiju sistemskim kortikosteroidima.
Additional tapping may be required if clumps remain. (See Figure B)
Može biti potrebno dodatno lupkanje ako se vide zaostale grudice. (vidjeti Sliku B)
Additional testing that might be required for suitability assessment:
Dodatna testiranja koja bi mogla biti potrebna radi procjene prikladnosti:
Additional tracing agents should not be injected within 30 minutes of Lymphoseek administration.
Dodatna sredstva za praćenje ne smiju se ubrizgavati unutar 30 minuta nakon primjene lijeka Lymphoseek.
Additional treatment (by a veterinarian) may be needed in animals with diarrhoea.
Dodatna terapija (veterinarska) može biti potrebna kod životinja s proljevom.
Additional treatments:
Dodatna liječenja:
Additional trials were conducted with liraglutide that included 1,901 patients in four unblinded randomised, controlled clinical trials (including 464, 658, 323 and 177 subjects per trial) and one double­blind, randomised, controlled clinical trial in subjects with type 2 diabetes and moderate renal impairment (279 patients).
Provedena su dodatna ispitivanja s liraglutidom u koja je uključen 1901 bolesnik u 4 otvorena randomizirana, kontrolirana klinička ispitivanja (uključujući 464, 658, 323 i 177 ispitanika po ispitivanju) i jedno dvostruko slijepo, randomizirano, kontrolirano ispitivanje u ispitanika sa šećernom bolešću tipa 2 i umjerenim oštećenjem bubrega (279 bolesnika).
Additionally for each vial the packs contain:
Dodatno se uz svaku bočicu u pakiranju nalazi:
Additionally for Enzepi 40,000 units gastro-resistant granules
Dodatno za Enzepi 40 000 jedinica želučanootporne granule indigotin (E132)
Additionally Imatinib Accord 100 mg tablets are available in perforated unit dose blister packs (PVC/PVdC/Alu) containing 30x1, 60x1,90x1, 120x1 or 180x1 film-coated tablets.
Pored toga, Imatinib Accord 100 mg tablete dostupne su u perforiranim blisterima djeljivim na jedinične doze (PVC/PVdC/Alu) u veličinama pakovanja od 30x1, 60x1, 90x1, 120x1 ili 180x1 filmom obložena tableta.
Additionally Imatinib Accord 100 mg tablets are available in PVC/PVdC/Alu perforated unit dose blister in pack-sizes of 30x1, 60x1, 90x1, 120x1 or 180x1 film-coated tablets.
Pored toga, Imatinib Accord 100 mg tablete dostupne su u PVC/PVdC/Alu perforiranim blisterima djeljivim na jedinične doze u veličinama pakovanja od 30x1, 60x1, 90x1, 120x1 ili 180x1 filmom obložena tableta.
Additionally Imatinib Accord 400 mg tablets are available in perforated unit dose blister packs (PVC/PVdC/Alu) containing 30x1, 60x1or 90x1 film-coated tablets.
Pored toga, Imatinib Accord 400 mg tablete dostupne su u perforiranim blisterima djeljivim na jedinične doze (PVC/PVdC/Alu) u veličinama pakovanja od 30x1, 60x1ili 90x1 filmom obložena tableta.
Additionally Imatinib Accord 400mg tablets are available in PVC/PVdC/Alu perforated unit dose blister in pack-sizes of 30x1, 60x1 or 90x1 film-coated tablets.
Pored toga, Imatinib Accord 400 mg tablete dostupne su u PVC/PVdC/Alu perforiranim blisterima djeljivim na jedinične doze u veličinama pakovanja od 30x1, 60x1 ili 90x1 filmom obložena tableta.
Additionally the use of post-infusion medications (e.g. inhaled corticosteroids, short and long acting bronchodilators) should be considered for patients with a history of obstructive pulmonary disorder to manage respiratory complications should they occur (see section 4.2).
Osim toga, u bolesnika s opstruktivnim plućnim poremećajem u anamnezi potrebno je razmotriti postinfuzijsku primjenu lijekova (npr. inhalacijskih kortikosteroida, kratkodjelujućih i dugodjelujućih bronhodilatatora) za zbrinjavanje respiratornih komplikacija, ako se pojave (vidjeti dio 4.2).
Additionally, 1 non-serious case of ‘light adaptation difficulties’ (not resolved) was reported in the non-interventional study INJECT.
Dodatno, je u neintervencijskoj studiji INJECT zabilježen 1 slučaj „poteškoće s adaptacijom na svjetlo“ (nije riješen).
Additionally, 49% of sunitinib patients had non-functioning tumours versus 52% of placebo patients and 92% patients in both arms had liver metastases.
Uz to, 49% bolesnika liječenih sunitinibom te 52% bolesnika koji su dobivali placebo imalo je nefunkcionalne tumore, a 92% bolesnika u obje skupine imalo je jetrene metastaze.
Additionally, ADRs from supportive study MCL-001 have been included in table 3.
Osim toga, u tablici 3 prikazane su i nuspojave iz dodatnog ispitivanja MCL-001.
Additionally, all 13 serotypes met the pre-defined non-inferiority criterion for IgG GMCs (lower bound of the 97.5% CI of GMC ratio [GMR] was greater than 0.5).
Pored toga, svih 13 serotipova ispunjavalo je unaprijed definiranu mjeru neinferiornosti za IgG GMC-ove (donja granica od 97,5%-tnog CI GMC omjera [GMR] bila je veća od 0,5).
Additionally, all patients must be vaccinated against meningococcus at least 2 weeks prior to receiving Soliris unless the risk of delaying Soliris therapy outweigh the risks of developing a meningococcal infection.
Uz to, svi bolesnici moraju biti cijepljeni protiv meningokoka najmanje 2 tjedna prije primanja lijeka Soliris, osim ako odgoda terapije Solirisom predstavlja veći rizik od rizika za razvoj menignokokne infekcije.
Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
Osim toga, nije se pokazalo da bi aripiprazol i dehidroaripiprazol mogli mijenjati metabolizam posredovan enzimom CYP1A2 in vitro.
Additionally, aztreonam-treated patients had fewer hospitalisations due to respiratory events (40 versus 58, p = 0.044) and fewer respiratory events requiring the use of i.v. or inhaled antipseudomonal antibiotics (84 versus 121, p = 0.004) than TNS- treated patients.
Pored toga, bolesnici liječeni aztreonamom imali su nižu stopu hospitalizacija zbog problema s dišnim sustavom (40 nasuprot 58, p = 0,044) te manje problema s dišnim sustavom koji su zahtijevali primjenu intravenskih ili inhalacijskih antipseudomonalnih antibiotika (84 nasuprot 121, p = 0,004) u odnosu na bolesnike liječene TNS-om.
Additionally, both amprenavir, the active metabolite of fosamprenavir, and ritonavir are primarily metabolised in the liver by CYP3A4.
Uz to, amprenavir, aktivni metabolit fosamprenavira, i rotonavir primarno se metaboliziraju u jetri putem CYP3A4.
Additionally, closure of all fistulae was achieved in 55% of infliximab-treated patients compared with 13% of placebo- treated patients (p=0.001).
Uz to, zatvaranje svih fistula postignuto je u 55% bolesnika liječenih infliksimabom, u odnosu na 13% bolesnika koji su primali placebo (p = 0,001).
Additionally, diarrhoea and diaper rash have been reported..
Dodatno su prijavljeni proljev i pelenski osip.
Additionally, diarrhoea and nappy rash have been reported.
Dodatno su prijavljeni proljev i pelenski osip.
Additionally, do not leave the pre-filled pen exposed to direct sunlight.
Osim toga, nemojte izlagati brizgalicu direktnoj sunčevoj svjetlosti.
Additionally, Eliquis is used to prevent stroke (caused by blood clots in the brain) and blood clots in other organs in adults with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart).
Nadalje, Eliquis se koristi za sprječavanje moždanog udara (uzrokovanog krvnim ugrušcima u mozgu) i krvnim ugrušcima u drugim organima u odraslih bolesnika s fibrilacijom atrija (nepravilnim brzim kontrakcijama gornjih srčanih komora).
Additionally, fatal reports of toxic epidermal necrolysis have been reported through postmarketing surveillance in patients receiving valdecoxib (the active metabolite of parecoxib) and cannot be ruled out for parecoxib (see section 4.8).
Uz to su tijekom praćenja lijeka nakon stavljanja u promet zabilježeni smrtni slučajevi zbog toksične epidermalne nekrolize u bolesnika koji su primali valdekoksib (djelatni metabolit parekoksiba) i koje se ne može isključiti za parekoksib (vidjeti dio 4.8).
Additionally, fewer adverse events were noted for polyuria (10% vs 19% of dogs), polydipsia (14% vs 23%) and marked sedation (14% vs 25 %) when comparing imepitoin to phenobarbital.
Osim toga, pri usporedbi imepitoina i fenobarbitala opažen je manji broj štetnih događaja s obzirom na poliuriju (10% naspram 19% pasa), polidipsiju (14% naspram 23%) i izrazitu sedaciju (14% naspram 25 %).
Additionally, fewer adverse events were noted for polyuria (10% vs 19% of dogs), polydipsia (14% vs 23%) and marked sedation (14% vs 25 %) when comparing imepitoin to phenobarbital.
Osim toga, pri usporedbi imepitoina i fenobarbitala opažen je manji broj štetnih događaja s obzirom na poliuriju (10% naspram 19% pasa), polidipsiju (14% naspram 23%) i izrazitu sedaciju (14% naspram 25%).
Additionally, following a 2-dose primary and booster schedule, protective immunity against hepatitis B persisted in ≥ 48% of subjects 11-12 years of age.
Nadalje, nakon 2-doznog primarnog cijepljenja i docjepljivanja zaštitna imunost protiv hepatitisa B održala se u ≥ 48% ispitanika u dobi od 11-12 godina.
Additionally, for patients with a history of obstructive pulmonary disorder, the use of post-infusion medications including short and long acting bronchodilators, and inhaled corticosteroids should be considered.
Osim toga, u bolesnika s opstruktivnim plućnim poremećajem u anamnezi potrebno je razmotriti postinfuzijsku primjenu kratkodjelujućih i dugodjelujućih bronhodilatatora te inhalacijskih kortikosteroida.
Additionally, for vaccine serotypes, protection against otitis media is expected to be substantially lower than protection against invasive disease.
Osim toga, očekuje se da će zaštita od upale srednjeg uha izazvane serotipovima cjepiva biti znatno niža od zaštite protiv invazivne bolesti.
Additionally, if after 6 hours the heart rate is <45 bpm or if the ECG at 6 hours after the first dose shows second degree or higher AV block, or if it shows a QTc interval ≥500 msec, monitoring should be extended at least for overnight and until the findings have resolved.
Uz to, ako je nakon 6 sati srčana frekvencija <45 otkucaja u min ili ako EKG 6 sati nakon prve doze pokazuje AV blok drugog ili višeg stupnja, ili ako pokazuje QTc interval ≥500 msek, praćenje treba produžiti barem preko noći i do povlačenja simptoma.
Additionally, if after 6 hours, the heart rate is <45 bpm, or the ECG shows new onset second degree or higher grade AV block or a QTc interval ≥500 msec, extended monitoring (at least overnight monitoring), should be performed, and until the findings have resolved.
Osim toga, ako je nakon 6 sati srčana frekvencija <45 otkucaja u minuti ili ako EKG pokazuje novi nastup AV bloka drugog ili višeg stupnja ili QTc interval ≥500 msek, treba obaviti produljeno praćenje (barem preko noći) te nastaviti dok se nalaz ne popravi.
Additionally, if you have any condition that could cause you to have a deficiency of vitamins A, D, E or K, your doctor may want to check your vitamin levels periodically while you are taking Cholestagel.
Osim toga, ako bolujete od neke bolesti koja bi mogla izazvati nedostatak vitamina A, D, E ili K, liječnik će možda tijekom liječenja lijekom Cholestagel povremeno htjeti kontrolirati razine tih vitamina.
Additionally, improvements in symptomatology and other organ dysfunction abnormalities were reported by the investigators in the case reports.
Dodatno, ispitivači su u prikazima slučajeva zabilježili i poboljšanja u simptomatologiji i drugim disfunkcijskim abnormalnostima organa.
Additionally, in 2 of the studies, cessation of visible signs of seizures within 10 minutes without recurrence within 1 hour after administration was observed in 56% to 70% of children.
Osim toga, u dva od tih ispitivanja, prestanak vidljivih znakova napadaja unutar 10 minuta bez ponavljanja unutar 1 sata nakon primjene, opažen je u 56% do 70% djece.
Additionally, in a placebo-controlled clinical trial in patients receiving MEC, safety was evaluated for 504 patients receiving a single dose of IVEMEND 150 mg compared to 497 patients receiving the control regimen.
Uz to, u placebom konroliranom ispitivanju u bolesnika koji su primali umjereno emetogenu kemoterapiju, sigurnost je bila procijenjena u 504 bolesnika koji su primili jednu dozu lijeka IVEMEND od 150 mg u usporedbi s 497 bolesnika koji su primali kontrolni režim.
Additionally, in a second study, treatment-experienced adults on a stable PI based highly active antiretroviral therapy (HAART) regimen were randomised to a once daily regimen containing emtricitabine or to continue with their PI-HAART regimen.
Tijekom dodatnog ispitivanja, odrasli pacijenti koji su prethodno liječeni te primaju visoko aktivno antiretrovirusno liječenje (HAART, highly active antiretroviral therapy) na temelju stabilnog PI-ja, slučajnim odabirom razvrstani su u dvije skupine: u jednoj su pacijenti liječeni emtricitabinom jedanput na dan, a u drugoj je nastavljeno liječenje PI- HAART terapijom.
Additionally, in a toxicology study in cynomolgus monkeys treated with Entresto at
Uz to, u toksikološkom ispitivanju u cynomolgus majmuna liječenih Entrestom u dozi od
Additionally, lesinurad led to a 6-8% decrease in International Normalised Ratio (INR) and Prothrombin Time (PT).
Nadalje, lesinurad je doveo do smanjenja međunarodnog normaliziranog omjera (INR, od engl. international normalised ratio) i protrombinskog vremena (PV) od 6 – 8%.
Additionally, lurasidone was superior to placebo on the predefined secondary endpoint Clinical Global Impression – Severity (CGI-S) scale.
Nadalje, lurasidon je bio superioran u odnosu na placebo na predefiniranoj drugoj mjeri ishoda ljestvice Opći klinički dojam – Težina (Clinical Global Impression – Severity (CGI-S)).
Additionally, Neoclarityn orodispersible tablet may be taken with or without a meal.
Nadalje, Neoclarityn raspadljive tablete za usta se mogu uzimati neovisno o obroku.
Additionally, no clinically relevant adverse effects were observed following 7-day twice daily dosing of up to 800 µg aclidinium bromide in healthy subjects.
Osim toga nisu zabilježene klinički značajne nuspojave nakon doze do 800 µg aklidinijeva bromida koja se u zdravih ispitanika primjenjivala dvaput dnevno tijekom 7 dana.
Additionally, no clinically relevant arrhythmias were observed during the conduct of the trial.
Osim toga, nisu bile zamijećene klinički značajne aritmije tijekom trajanja ispitivanja.
Additionally, other adverse events have been reported with post- marketing use of ProQuad and/or in clinical studies and post-marketing use of either the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., the monovalent component vaccines of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., or Varicella Vaccine live (Oka/Merck).
Nadalje, drugi štetni događaji prijavljeni su prilikom primjene cjepiva ProQuad nakon njegova stavljanja u promet i/ili u kliničkim ispitivanjima i prilikom primjene cjepiva protiv morbila, parotitisa i rubele proizvođača Merck & Co., Inc., monovalentnih cjepiva protiv morbila, parotitisa i rubele proizvođača Merck & Co., Inc. ili živog cjepiva protiv varičele (Oka/Merck) nakon njihova stavljanja u promet.